MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers
This open-label trial (n=30) will test whether the MDMA-assisted psychotherapy protocol is also effective in treating PTSD incurred by healthcare workers during the Covid pandemic.
Details
This single-group, open-label Phase II study evaluates safety and efficacy of MDMA-assisted therapy in health-care workers with work-related post-traumatic stress following the COVID-19 pandemic.
Participants complete screening and three preparatory sessions, then receive three all-day MDMA dosing sessions spaced ~3–5 weeks apart; each dosing is followed by three 90-minute integration sessions.
Outcome assessments occur at treatment termination 2–4 weeks after active treatment and again at 12 months to assess durability; safety monitoring includes medication tapering and medical screening during enrollment.